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Abstract
Several controlled clinical studies have evaluated the potential of the infection biomarker procalcitonin (PCT)
to improve the diagnostic work-up of patients with bacterial infections and its influence on decisions regarding
antibiotic therapy. Most research has focused on lower respiratory tract infections and critically ill sepsis patients. A
clinical utility for PCT has also been found for patients with urinary tract infections, postoperative infections, meningitis,
and patients with acute heart failure with possible superinfection (i.e., pneumonia). In these indications, PCT
levels measured on hospital admission were found to substantially reduce the initiation of antibiotic treatment in
low-risk situations (i.e., bronchitis, chronic obstructive pulmonary disease exacerbation). For more severe infections
(i.e., pneumonia, sepsis), antibiotic stewardship by monitoring of PCT kinetics resulted in shorter antibiotic treatment
durations with early cessation of therapy. Importantly, these strategies appear to be safe without increasing the risk for
mortality, recurrent infections, or treatment failures. PCT kinetics also proved to have prognostic value correlating with
disease severity (i.e., pancreatitis, abdominal infection) and resolution of illness (i.e., sepsis). Although promising findings
have been published in these different types of infections, there are a number of limitations regarding PCT, including
suboptimal sensitivity and/or specificity, which makes a careful interpretation of PCT in the clinical context mandatory.
This narrative review aims to update clinicians on the strengths and limitations of PCT for patient management,
focusing on research conducted within the last 4 years.
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Background
There are important limitations to consider when
using conventional diagnostic markers, such as blood
cultures and inflammatory markers (i.e., C-reactive
protein [CRP]), for patients with a clinical suspicion
of infection, particularly in regard to suboptimal sen-
sitivity and specificity [1]. These limitations often
leave physicians with ambiguity regarding the necessity of
the use of antibiotic treatment. As a consequence, un-
necessary and prolonged exposure to antimicrobial agents
adversely affect patient outcomes (e.g., risk for Clostrid-
ium difficile infection), while inappropriate antibiotic ther-
apy increases antibiotic resistance in patients, resulting in
a public health threat. A growing body of evidence sup-
ports the use of the infection marker procalcitonin (PCT)
to improve the diagnosis of bacterial infections and to
indicate resolution of infection, thereby helping to moni-
tor patients and guide antibiotic therapy.
Based on a review published in 2011 [2], this current
narrative review aims to update clinicians on (promising)
new indications for PCT in patient management by fo-
cusing on research studies published from 2012 to the
end of 2016. The evidence from observational and inter-
ventional research is ordered by different types of infec-
tions and study designs. Proposed PCT cut-offs and the
main conclusions of relevant studies are summarized in
Table 1 and graphically displayed in Fig. 1.
Infections of the respiratory tract
Infections of the respiratory tract, including bron-
chitis, community-acquired pneumonia (CAP), and
acute exacerbated chronic obstructive pulmonary dis-
ease (AECOPD), are the most important drivers for
antibiotic (over-) treatment and thereby contribute to
the increasing rate of antibiotic multi-resistance. The
diagnosis of respiratory infections relies mainly on
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Table 1 Overview of studies investigating the use of procalcitonin in different types and sites of infections
Type of infection New studies
since 2010?




Main conclusions Selected references
since 2012
Pulmonary AECOPD yes RCT (N = 120),
meta-analysis
<0.25 ++ PCT reduces initiation of antibiotic
treatment in the ED without
adverse outcomes
[7, 12]
Asthma yes RCT (N = 216) <0.1–0.25 ++ PCT reduces initiation of antibiotic







<0.1–0.25 ++ PCT reduces initiation of antibiotic











+++ PCT shortens length of antibiotic





yes RCT (N = 78) <0.25 ++ PCT reduces initiation of antibiotic





no RCT (N = 458, 702) <0.1–0.25 +++ PCT reduces initiation of antibiotic








<0.21–0.25 ++ PCT helps in identification of bacterial
superinfection in acute heart failure,





<0.5 + PCT is a predictor of poor outcome,





yes Observational <0.5; 80%
decrease
++ PCT-guided therapy was associated
with lower antibiotic exposure with




NR + PCT is a marker of complicated
appendicitis, low value for
diagnosing appendicitis
[92]
Pancreatitis yes RCT (N = 71) <0.5 ++ PCT reduces antibiotic exposure
compared to prophylactic antibiotic









yes Observational <0.25–1.47 ++ PCT levels correlate with risk for
positive blood cultures
[19, 27]
Neutropenia yes RCT (N = 62) NR – PCT is not useful to manage





yes RCT (N = 1575) <0.5; 80%
decrease
+++ PCT reduces antibiotic exposure and







NR + Low PCT post-surgical ensure safe






<0.5–2.0 ++ Low PCT suggests absence of
perioperative infection and enables
early discharge
Other Arthritis yes Observational <0.5 + PCT identifies infection in patients
with rheumatoid arthritis
[94]
Erysipelas yes Observational <0.1 + PCT differentiates erysipelas from DVT [81]
Meningitis no RCT, meta-analysis
(N = 2058)
<0.5 +++ PCT reduces AB treatment during viral
outbreak; serum PCT with CSF lactate
reliably identifies bacterial meningitis
[72, 74]
Abbreviations: AB antibiotic, AECOPD acute exacerbation of chronic obstructive pulmonary disease, CSF cerebral spinal fluid, CRP C-reactive protein, ED emergency
department; ICU intensive care unit; NR not reported, PCT procalcitonin, RCT randomized controlled trial. The level of evidence in favor or against PCT for each in-
fection was rated by two of the coauthors (PS, RSA) independently and disagreements were resolved by consensus. +: moderate evidence in favor of PCT; ++:
good evidence in favor of PCT; +++: strong evidence in favor of PCT; –: no evidence in favor of PCT
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clinical criteria (e.g., cough, dyspnea, fever) and chest
radiography to document infiltration of the lung [3].
Identification of the pathogen by culture or polymer-
ase chain reaction (PCR) methods has low sensitivity,
and thus may not rule out bacterial infection [3]. For
some types of infections, such as Legionella, clinical
scores can help to assess the risk of infection [4, 5].
Several observational studies as well as interventional
trials have established the usefulness of PCT in pa-
tients with respiratory infections.
A 2012 Cochrane meta-analysis based on individual
patient data from 14 randomized controlled trials
(RCTs) focused on effects of PCT in patients with re-
spiratory infections [6, 7]. The studies had somewhat
similar PCT protocols with recommendations for or
against initiation or continuation of antibiotic therapy
based on initial PCT levels, PCT kinetics over time (i.e.,
80% PCT decrease from peak), or both, in combination
with the clinical presentation and resolution of illness
(Figs. 2 and 3) [8]. The cut-offs were adapted to the clin-
ical setting and the acuity of presentation, with cut-offs
of 0.25 (0.1) ng/ml in respiratory infections and 0.5 ng/ml
in sepsis [9]. The meta-analysis found a strong reduction
in the initial use of antibiotics, by around 60–70%, for
low-severity respiratory infection (i.e., bronchitis, upper
respiratory infections, AECOPD) [6, 9, 10]. In cases of
higher-severity respiratory infection (i.e., pneumonia),
monitoring of PCT resulted in earlier cessation of anti-
biotic treatment with a relative reduction in the duration
of antibiotic treatment of around 40% for pneumonia and
around 25% in the critical care of patients with sepsis
caused by lung infections. Based on these studies, recent
respiratory infection guidelines state that “… biomarkers
can guide treatment duration by the application of prede-
fined stopping rules for antibiotics. It has been shown that
such rules work even in most severe cases, including
pneumonia with septic shock …” [11], thereby emphasiz-
ing the concept of using a biomarker to guide the duration
of antibiotic treatment.
An Italian RCT of patients with AECOPD published
in 2016 found that a point-of-care PCT measurement
was helpful in directing antibiotic therapy on admission
[12]. In general, point-of-care technology has the advan-
tage of high availability and short time to results for cli-
nicians [13]. Patients randomized to the PCT group had
a shorter antibiotic treatment course of 3.5 days com-
pared to 8.5 for patients in the control group. The
shorter duration in the PCT group did not negatively
affect the resolution of illness or mortality.
Little research has so far focused on PCT use in pa-
tients with asthma and cystic fibrosis. A 2014 RCT in
China of 216 patients with asthma also found PCT to be
helpful in guiding antibiotic therapy, resulting in a re-
duction of prescribed antibiotics (48.9% versus 87.8%)
Fig. 1 Summary of evidence regarding procalcitonin (PCT) for diagnosis and antibiotic stewardship in organ-related infections. While for some
infections, intervention studies have investigated benefit and harm of using PCT for diagnosis and antibiotic stewardship (left side), for other infec-
tions only results from diagnostic (observation) studies are available (right side). +: moderate evidence in favor of PCT; ++: good evidence in favor
of PCT; +++: strong evidence in favor of PCT; – no evidence in favor of PCT
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and antibiotic exposure (relative risk 0.56, 95% confi-
dence interval [CI] 0.44–0.70) [14]. There were no sig-
nificant differences between the two groups in clinical
recovery; length of hospital stay; or clinical, laboratory,
and spirometry outcomes. For patients with idiopathic
pulmonary fibrosis (IPF), a small RCT in China of 78 pa-
tients found a shorter treatment length (8.5 ± 6.6 days
versus 14.2 ± 5.2 days) and fewer antibiotic prescriptions
(26 versus 35 patients) in the PCT-guided group versus
standard care. These small RCTs suggest that a PCT-
guided protocol is superior to standard care in patients
with suspected infection and underlying pulmonary dis-
ease (asthma, COPD, IPF) and reduces antibiotic con-
sumption [15].
Novel studies have looked at the effect of PCT testing in
“real life” in patients with respiratory infections. The Pro-
REAL study included 1759 patients from Switzerland,
France, and the USA and validated previous results from
well-controlled RCTs [16, 17]. Importantly, compliance in
trials is often higher compared to compliance in real life
and post-study registries are thus important to understand
how physicians use new diagnostic tools in clinical
Fig. 3 Procalcitonin (PCT) algorithm in patients with sepsis in the intensive care unit (ICU). In critically ill patients in the ICU, cut-offs are higher
and initial empiric antibiotic therapy should be encouraged in all patients with suspicion of sepsis. PCT cut-offs are helpful in the subsequent days
after admission to shorten the course of antibiotic therapy in patients with clinical improvement
Fig. 2 Procalcitonin (PCT) algorithm in patients with respiratory tract infections in the emergency department. The clinical algorithm for antibiotic
stewardship in patients with respiratory tract infections in the emergency department encourages (>0.5 ng/ml or >0.25 ng/ml) or discourages
(<0.1 ng/ml or <0.25 ng/ml) initiation or continuation of antibiotic therapy more or less based on specific PCT cut-off ranges. Abbreviations: AB
antibiotic, LRTI lower respiratory tract infection, ICU intensive care unit, PSI pneumonia severity score
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practice. Algorithm compliance in the ProREAL study
overall was 68.2%, with differences between diagnoses,
outpatients and inpatients, algorithm-experienced and
algorithm-naive centers, and countries. Antibiotic therapy
duration was significantly shorter if the PCT algorithm
was followed compared with when it was overruled (5.9
versus 7.4 days; difference −1.51 days, 95% CI −2.04 to
−0.98; p < 0.001). Another large propensity score-matched
analysis investigated the impact of one to two PCT deter-
minations on day 1 in the intensive care unit (ICU) on
healthcare utilization and cost; this research database
comprised 33,569 PCT-managed patients and 98,543 con-
trols [18]. PCT utilization was associated with significantly
decreased total and ICU length of stay, lower hospital
costs, and lower total antibiotic exposure. Thus, real-life
data showed similar effects compared to RCT data, em-
phasizing the importance of continuous education to in-
crease knowledge and confidence in PCT protocols.
Blood stream infection
Currently no gold standard exists for detecting blood
stream infection (BSI). Yet, this is a key factor in tar-
geted therapy and may improve survival. Blood culture
is the most reliable diagnostic modality and samples for
culturing are collected routinely in patients in the emer-
gency department. Blood cultures give important informa-
tion about the type of microorganism and its susceptibility
to antibiotic treatment. However, only a small proportion
of cultures give positive results and 40–90% remain nega-
tive [17, 19]. A large retrospective study from China found
that only 440 of 2829 blood cultures (15.5%) were positive
[20]. Furthermore, time to result is long, which precludes
important initial treatment decision-making.
Multiple clinical scores and biomarkers have been in-
vestigated for their ability to predict blood culture posi-
tivity. A meta-analysis from 2013, including 3244
critically ill patients classified using the former definition
of either sepsis or systemic inflammatory response syn-
drome (SIRS) of non-infectious origin, pooled the diag-
nostic power of PCT. Studies between 1996 and 2011
were included and showed that PCT had a high discrim-
inatory ability (area under the curve [AUC] of 0.85), with
pooled sensitivity and specificity of 0.77 and 0.79, re-
spectively [21]. Similar results were reported in a large
retrospective study from Korea in 2012 that included
3343 patients, showing an AUC of 0.76 for PCT in dis-
criminating bacteremia from non-bacteremia [22].
In addition to biomarkers, clinical signs can also help
in the assessment of the likelihood of culture positivity.
One observational cohort study from 2015 that included
1083 patients who had blood culture drawn in the emer-
gency department investigated several clinical scores and
blood biomarkers, including the ability of PCT to predict
blood culture sampling [19]. In blood culture-positive
cases (N = 104, 9.6%) the Shapiro score and initial PCT
concentration performed best, with AUCs of 0.729 and
0.803, respectively. Combining the Shapiro score and
PCT significantly increased the AUC to 0.827. By limit-
ing blood culture sampling only to patients with either a
Shapiro score ≥4 or PCT >0.1 ng/ml would have re-
duced negative sampling by 20.2% while still identifying
100% of pathogens. A large retrospective study from
2016 in China including 2952 cases found an AUC of
0.713 for PCT, with an optimal cut-off value of 1.46 ng/ml
for distinguishing negative from positive blood cultures
(sensitivity 70%, specificity 64.5%) [20]. In contrast, an
Austrian study published in 2014 that included 898 pa-
tients with 666 confirmed positive blood cultures (74.2%)
found that PCT performed only moderately, with an AUC
of 0.675. Even at a cut-off level of 0.1 ng/ml, PCT failed to
correctly identify 46 positive blood cultures (7%) while re-
ducing negative blood culture sampling by 20%. The re-
searchers concluded that the false negative ratio was too
high to implement blood culture sampling by PCT only
[23]. These controversial results point out the need for
further studies on this topic.
Interestingly, studies have also investigated PCT to as-
sess whether blood cultures that test positive have been
contaminated. Several studies found that PCT showed
good discrimination between BSI and contamination
with an AUC of 0.86 [22, 24]. Additionally, in a PCR
diagnostic (SeptiFast) test, a PCT value of <0.37 ng/ml
had a 99% negative predictive value for this assay [25].
Studies have also investigated how well PCT correlates
with types of pathogens. Different PCT cut-off levels
suggest different bacterial species, with higher concen-
trations for Gram-negative Bacteriaceae (AUC 0.81 at
cut-off 6.47 ng/ml) [20, 26]. Furthermore, PCT has been
shown to be helpful in differentiating infectious disease
from autoimmune disease. In SIRS patients with nega-
tive blood cultures, PCT can differentiate septic from
non-septic causes (AUC 0.892). A PCT cut-off value of
1.47–2 ng/ml shows the best performance (sensitivity
92%, specificity 83%) [27, 28].
Sepsis, severe sepsis, and septic shock
Sepsis, as defined by SIRS criteria and organ dysfunc-
tion, and septic shock are common diseases in the ICU
and require fast and appropriate antimicrobial therapy.
Multiple studies have investigated whether a PCT-
guided algorithm can optimize the therapeutic approach
in these patients, mainly by monitoring PCT kinetics
and stopping antibiotics once PCT has dropped to levels
<0.5 ng/ml or by at least 80–90% of the peak in combin-
ation with clinical improvement. A 2013 meta-analysis
including 1075 patients with sepsis or septic shock
found overall reduced antibiotic treatment courses
(6 days versus 8 days) when PCT was used to guide
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therapy compared to routine care. There was no in-
crease in 28-day or in-hospital mortality or in length of
stay in the ICU or the hospital. The authors do stress
that there was heterogeneity in PCT protocols across tri-
als with regard to different cut-off values or different al-
gorithms for medical or surgical patients [29]. A large
RCT published in 2016 in the Netherlands evaluated the
use of PCT to de-escalate and stop antibiotics in 1575
critically ill patients who had received antibiotics <24 h
before inclusion in the study for an assumed or proven
infection [30]. The study found that the PCT-guided
protocol shortened length of antibiotic treatment (5 days
versus 7 days in the first 28 days of admission) and low-
ered 28-day mortality from 25 to 19.6% [30]. Although
the cause of the reduced mortality remained unclear, a
lower risk of antibiotic-associated side effects and im-
proved therapeutic monitoring could have been factors
[31]. Very similar results in a recently published RCT
from Germany also found a lower antibiotic consump-
tion using PCT, but no benefit in mortality [32].
Interestingly, a multicentre trial including 11 Austra-
lian ICUs and almost 400 patients found only a modest
effect of PCT testing in regard to antibiotic reductions
(median number of antibiotic treatment days 9 versus
11) [33]. The authors used a 0.1 ng/ml cut-off to stop
antibiotic treatment, which may explain the differences
to other sepsis trials that used a 0.5 ng/ml cut-off.
In addition, similar to other sepsis markers, PCT has
been found to predict the severity of illness. A meta-
analysis from 2015 showed a significant difference in PCT
on day 1 and 3 between survivors and non-survivors. But
cut-off values varied between studies and it was not pos-
sible to pool data to a common cut-off value. There have
been several trials investigating prognostic scores to deter-
mine the severity of SIRS, such as the Predisposition, In-
sult, Response, Organ dysfunction (PIRO) model and the
Mortality in Emergency Department Sepsis (MEDS) score
[34, 35]. An important consideration in septic patients is
that renal impairment and a reduced glomerular filtration
rate may lower PCT clearance and levels thus may be
higher than expected [36, 37].
Congestive heart failure
Patients with congestive heart failure (CHF) often
present to the ED with dyspnea. It can be challenging to
differentiate acute heart failure from a lung infection.
PCT may be helpful in this indication for ruling in or
ruling out an infection [38–41]. PCT has thus been pro-
posed as a promising marker for cardiologists [41]. A
large study from China found that the severity of CHF
was also a predictor for PCT levels in patients with in-
fection complicated by heart failure [40]. A large obser-
vational study found a worse outcome in patients with a
diagnosis of CHF and an elevated PCT concentration
(>0.21 ng/mL) if they were not treated with antibiotics
(p = 0.046). Patients with low PCT values (<0.05 ng/mL)
had a better outcome if they did not receive antibiotic
therapy (p = 0.049). Similar results were also found in a
secondary analysis of a previous randomized trial and it
was speculated that more appropriate treatment deci-
sions due to PCT monitoring could explain this effect
(diuretic therapy with liquid restriction in case of acute
heart failure versus antibiotics and fluids in case of infec-
tion) [42, 43]. The role of PCT in the setting of decom-
pensated CHF has potential and needs to be elucidated
in future studies. Results from the IMPACT-EU trial
may be of high relevance (https://clinicaltrials.gov/ct2/
show/NCT02392689).
Urinary tract infection
Several new publications have focused on the utility of
PCT in urinary tract infection (UTI) with or without
sepsis [44–46]. A threshold of 1.16 ng/ml was proposed
by Julian-Jemenez et al. [44] as having the largest area
under the receiver operating characteristic curve at
0.993 and therefore the most relevant in guiding medical
decision-making [44]. The utility of PCT in this setting
was also investigated in a Swiss RCT [47]. The study
showed a reduction in antibiotic use of 30% compared
to the standard treatment. The elaborated algorithm
combined serum PCT concentration and quantitative
pyuria measurements [47]. Patients were classified with
uncomplicated or complicated UTI and as outpatients
versus inpatients, resulting in different antibiotic admin-
istration, different length of treatment, or a monitored
approach with measuring of PCT and degree of pyuria.
There were no negative effects. The authors concluded
that a PCT/pyuria-based approach is safe in terms of
outcome and has the potential to reduce antibiotic
consumption.
Postsurgical infection
A physiological rise in PCT concentration is observed in
postoperative patients due to surgical stress-triggered in-
flammation. The highest values are measured on the sec-
ond postoperative day and usually show a sharp decline
thereafter. Therefore, very high initial levels or non-
dropping levels of PCT suggest postsurgical infection
[48]. A chronological sampling was shown to be useful
and superior to on-time sampling and predicted compli-
cations in the postoperative course [49]. Positive results
for PCT were shown in studies of cardiopulmonary sur-
gery, open aortic repair surgery, hip replacement, and
liver transplantation [48–52]. Dong et al. found that
PCT had a high discriminative power between septic
and non-infective SIRS after cardiac surgery (cut-off
value 0.47 ng/ml) [53]. PCT was also found to be useful
to confirm surgical success after necrotizing fasciitis
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[54]. In complicated abdominal infection after surgery,
high PCT correlates with mortality rates [55]. In
addition, PCT is also beneficial in the setting of postop-
erative fever [56]. Several observational studies have
questioned the reliability of PCT in postoperative pa-
tients with intra-abdominal infection. Although the
negative predictive value was found to be high, which
may help to ensure early discharge [57], the specificity
was quite low. Also, a meta-analysis including 2692 pa-
tients after colorectal surgery showed no advantage of
PCT compared to CRP regarding diagnostic accuracy
and mortality prediction [58]. This was confirmed re-
cently in a similar large prospective study including 501
patients [59]. Thus, further investigation is needed in the
surgical setting, and also to compare the accuracy and
cost-effectiveness of PCT with other infection markers
such as CRP.
Abdominal disease and abdominal infection
Several studies have investigated the use of PCT in pa-
tients with abdominal infection. In patients with liver
cirrhosis, one study found that PCT could identify com-
plications through bacterial infection [60, 61]. Similar
results were found for acute pancreatitis, with PCT a
good predictor of accompanied perforation or abscess
[62–64]. In a small RCT of patients with acute pancrea-
titis, a PCT-guided antimicrobial approach was shown
to be safe and effective compared to a control group
that received prophylactic antibiotic treatment for
2 weeks [65]. Furthermore, in patients presenting with
secondary peritonitis, PCT-guided therapy was shown
to reduce antibiotic consumption by 50% [66]. There
are currently no studies evaluating the role of PCT in
infected diverticulosis and more studies are strongly
needed in general to evaluate the use of PCT-guided
treatment in abdominal infection.
Endocarditis
Few studies have investigated the use of serum PCT in
infectious endocarditis. Nevertheless, one large meta-
analysis by Yu et al. found that PCT was not superior
compared to CRP, and therefore not suitable in routine
diagnostic [67]. However, Cornelissen et al. found PCT
useful in the prediction of poor outcome (cut-off 0.5 ng/
ml, sensitivity 73%, specificity 79%), with an odds ratio
of 12.8 (95% CI 2.5–66.2) for finding Staphylococcus
aureus in blood cultures [68].
Febrile neutropenia
In patients with haematological malignancies with
newly developed febrile neutropenia (FN), PCT is an
accurate marker of infection as well as a predictor of
severity [69, 70]. A 2015 meta-analysis provided the
first large-scale clinical evidence on the validity of
PCT in discriminating bacterial infection from other
cause of fever in patients with FN [71]. In this study
of 1960 febrile episodes, a positive likelihood ratio of
5.49 was found for PCT being a good marker for in-
fection. Overall, PCT had a specificity of 0.88 but low
sensitivity of 0.65, resulting in a suboptimal negative
likelihood ratio of 0.4. Taken together, PCT might be
specific, but not sensitive, in differentiating severe
bacterial infection from other systemic inflammation
or viral infection. The authors state that, with regards
clinical implications, the use of PCT is valuable as a
diagnostic aid to confirm infection. However, the
negative likelihood ratio (0.4) is unacceptably high for
guiding antimicrobial therapy and PCT is therefore
not suitable for predicting treatment cessation in pa-
tients with FN. Moreover, a recent study showed a
significant correlation between initial PCT concentra-
tion and ICU admission (AUC 0.93) and mortality
(AUC 0.86) [70].
Meningitis
Several older studies evaluated PCT-guided therapy in
meningitis and determined that PCT-guided therapy re-
duces antimicrobial consumption during a viral outbreak
[72]. Two recent meta-analyses confirmed PCT’s accur-
acy in differentiating viral from bacterial meningitis [73,
74]. The most recent meta-analysis from 2016 included
2058 subjects and showed a sensitivity of 0.95 (95% CI
0.89–0.97), a specificity of 0.97 (95% CI 0.89–0.99), a
positive likelihood ratio of 31.7 (95% CI 8.0–124.8), and
a negative likelihood ratio of 0.06 (95% CI 0.03–0.11).
The diagnostic performance was even better when com-
bined with cerebrospinal fluid lactate. Serum PCT was
found to be more sensitive and specific than cerebrospinal
fluid PCT [74]. Furthermore, PCT was useful for prognos-
tication of poor outcome, follow up of treatment, and for
differentiating from tuberculous meningitis [75].
Septic arthritis
Several small studies have investigated the role of PCT
in septic arthritis and bacterial osteomyelitis. In particu-
lar, in patients with rheumatologic disease, the differenti-
ation between acute rheumatoid flare and infectious
arthritis is of upmost importance. PCT was found to be
a reliable marker at a cut-off of 0.4 ng/ml and is indi-
cated especially if arthrocentesis cannot be performed
[76]. The same is true in acute gouty arthritis, because
PCT rises together with aseptic-gouty inflammation and
can therefore be falsely positive [77, 78]. A PCT value
beyond 0.5 ng/ml does not, however, rule out bacterial
infection and appropriate treatment may be indicated
[79]. Otherwise, PCT accuracy is highest when measured
in fresh joint fluid [80]. We found no new studies evalu-
ating PCT-guided antibiotic therapy in septic arthritis.
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Erysipelas
Few studies have investigated the use of PCT in local
infections such as erysipelas. Early differentiation from
similarly presenting deep vein thrombosis (DVT) based
solely on clinical signs and symptoms is challenging. A
2015 study in Switzerland investigated the use of PCT
to help physicians in discriminating between these in-
fections. At a cut-off value of 0.1 ng/ml, PCT had a
sensitivity of 0.57, a specificity of 0.82, and a positive
predictive value of 0.86. Levels of PCT also correlated
with the severity of erysipelas, with a stepwise increase
according to SIRS criteria. Thus, PCT was found to be
highly discriminant for differentiation between erysip-
elas and DVT but further research is warranted [81].
Limitations
This narrative review has limitations. First, we did
not do a systematic review for each type of infection
but have selected studies based on a PubMed search
and the authors’ expertise. Our conclusions may thus
be too enthusiastic. Second, most of the studies did
not blind patients and/or investigators and thus are
subject to possible bias. Third, we focused on studies
published between 2012 and mid-2016. Papers before
or after this time frame may have been missed. We
have also not discussed in detail other markers of in-
fection such as CRP. However, there is a lack of well-
done and large studies comparing the effect of both
markers when used in the context of antibiotic stew-
ardship [82, 83].
Importantly, PCT is far from being a perfect marker
and levels must be evaluated in the context of a care-
ful clinical and microbiological patient assessment.
Because the kinetics of PCT are of particular diagnos-
tic and prognostic importance, repeated measure-
ments should be performed. This is particularly true
for persistently sick patients and in situations in
which antibiotics are withheld. The limitations of
PCT include false-positive and false-negative results
[84]. PCT levels can increase in the absence of a bac-
terial infection in patients with severe trauma or after
surgery [84–86]. Here, PCT usually shows a rapid de-
cline in follow-up measurements when the patient re-
covers. Also, patients with chronic renal failure can
have a slower decrease in PCT levels. PCT levels can
also be low in the early course or localised state of
an infection, with later measurements showing an in-
crease in levels. Again, repeated PCT measurements
are advised in case of uncertainty. Another important
consideration is the cost of measuring PCT. While
some reviews found PCT to be cost-efficient in re-
spiratory infections when antibiotics can be reduced
by the measurement of this marker [87], this may not
be true for other indications.
Summary, future directions, and conclusions
This update of a previous narrative review found several
interesting new clinical settings in which PCT-guided
therapy could help to reduce antibiotic exposure by de-
creasing either initiation or duration of treatment. Par-
ticularly, controlled clinical studies have found that PCT
improves the management of patients with lower re-
spiratory tract infections and critically ill sepsis patients,
as well as patients with UTIs, postoperative infections,
meningitis, and acute heart failure with possible super-
infection (i.e., pneumonia). Recording PCT levels on
hospital admission was found to substantially reduce the
initiation of antibiotic treatment in low-risk situations
(i.e., bronchitis, AECOPD). For more severe infections
(i.e., pneumonia, sepsis), antibiotic stewardship by moni-
toring PCT kinetics resulted in shorter antibiotic treat-
ment duration by early cessation of therapy. These
strategies appear to be safe without increasing the risk
for mortality, recurrent infections, or treatment failure.
PCT kinetics have also proved to have prognostic value,
correlating with disease severity (i.e., pancreatitis, ab-
dominal infection) and resolution of illness (i.e., sepsis).
While there is strong evidence regarding antibiotic stew-
ardship in respiratory infection and sepsis, PCT has not
been as well studied for other types of infections. Thus,
future research should focus on non-respiratory infec-
tions and investigate whether PCT improves antibiotic
decisions in these patients. PCT should also be com-
pared to other markers, such as CRP, in regard to diag-
nostic accuracy and cost-effectiveness.
Emerging bacterial resistance to antimicrobial agents
calls for more effective efforts to reduce the unnecessary
and prolonged use of antibiotics in self-limiting non-
bacterial and resolving diseases [88]. Healthcare profes-
sionals share a common goal of achieving symptom
relief from infection as fast as possible and often see an-
tibiotics as the best means to achieve this goal. This
“one size fits all” approach, however, does not answer
the basic questions of who truly benefits from antibiotic
therapy and what would be the optimal duration of
treatment. There is a growing body of literature support-
ing the use of PCT as a persuasive, evidence-based ap-
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